Provided by Tiger Trade Technology Pte. Ltd.

Tonix Pharmaceuticals

13.59
+0.03000.22%
Post-market: 13.47-0.1202-0.88%19:59 EDT
Volume:490.50K
Turnover:6.68M
Market Cap:233.08M
PE:-1.09
High:13.98
Open:13.52
Low:13.30
Close:13.56
52wk High:31.55
52wk Low:9.40
Shares:17.15M
Float Shares:14.99M
Volume Ratio:0.87
T/O Rate:3.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-12.4882
EPS(LYR):-14.5713
ROE:-81.82%
ROA:-46.84%
PB:1.05
PE(LYR):-0.93

Loading ...

Tonix publishes investor deck highlighting TONMYA fibromyalgia launch strategy

Reuters
·
May 15

Tonix Pharmaceuticals to Present Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at ISPOR 2026

GlobeNewswire
·
May 14

Tonix Pharmaceuticals to present at RBC Capital Markets Global Healthcare Conference

Reuters
·
May 13

Tonix Pharmaceuticals to Participate in Two Investor Conferences in May

GlobeNewswire
·
May 13

Analysts’ Top Healthcare Picks: Dexcom (DXCM), Tonix Pharma (TNXP)

TIPRANKS
·
May 12

Tonix Pharmaceuticals reports Q1 EPS ($2.93) vs. ($2.84) last year

TIPRANKS
·
May 12

Tonix Pharmaceuticals Holding Corp reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 12

Tonix Pharmaceuticals Q1 EPS $(2.93) Misses $(2.43) Estimate, Sales $6.878M Beat $6.100M Estimate

Benzinga Earnings
·
May 12

Tonix Q1 FY26 net loss widens to $40.2 million; net product revenue rises to $6.9 million

Reuters
·
May 12

Tonix Pharmaceuticals: Expect to Begin Phase 2 Study of Tonmya for Treatment of Major Depressive Disorder (Mdd) Mid-Year

THOMSON REUTERS
·
May 12

Tonix Pharmaceuticals: to Initiate Adaptive Phase 2 Field Study for Prevention of Lyme Disease in U.S. in H1 2027 for Tnx-4800, Pending FDA Agreement

THOMSON REUTERS
·
May 12

Tonix Pharmaceuticals Q1 EPS USD -2.93

THOMSON REUTERS
·
May 12

Tonix Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Highlights

GlobeNewswire
·
May 12

Alliance Global Partners Keeps Their Buy Rating on Tonix Pharma (TNXP)

TIPRANKS
·
May 11

EXE, IP, ESPR, CMPS, TNXP Trending With Analysts

TIPRANKS
·
May 09

Tonix Pharmaceuticals Holding Corp expected to post a loss of $2.43 a share - Earnings Preview

Reuters
·
May 08

Tonix Pharmaceuticals shareholders approve 2026 stock incentive plan at annual meeting

Reuters
·
May 08

Tonix Pharmaceuticals Secures Commercial Payer Coverage for TONMYA®, Providing Access for ~35 Million U.S. Patients

GlobeNewswire
·
May 06

Tonix publishes TNX-4800 Lyme disease prevention presentation

Reuters
·
May 06

Tonix Pharma (TNXP) Receives a Buy from Alliance Global Partners

TIPRANKS
·
May 04